Efficacy of Paliperidone Palmitate in Schizophrenia
Author Information
Author(s): Larry Alphs, Cynthia A Bossie, Jennifer K Sliwa, Yi-Wen Ma, Norris Turner
Primary Institution: Ortho-McNeil Janssen Scientific Affairs, LLC
Hypothesis
Does acute treatment with paliperidone palmitate improve symptoms in severely ill schizophrenia patients?
Conclusion
Acute treatment with 234 mg of paliperidone palmitate significantly improved psychotic symptoms compared to placebo by day 4.
Supporting Evidence
- Mean PANSS total scores improved significantly with paliperidone palmitate versus placebo at day 4 and day 8.
- Significant PANSS improvement persisted at all subsequent time points in the 234-mg group versus placebo.
- CGI-S and PSP scores improved significantly in the 234-mg and 156-mg groups versus placebo at end point.
Takeaway
This study shows that a shot of paliperidone palmitate can help people with severe schizophrenia feel better quickly.
Methodology
This was a post hoc analysis of a 13-week, randomized, double-blind, placebo-controlled trial.
Potential Biases
Potential bias due to the study being a post hoc analysis of a trial not specifically designed for this subgroup.
Limitations
The study was a post hoc analysis and may not generalize to all patients with schizophrenia.
Participant Demographics
Participants were adults with schizophrenia, 88.1% had marked illness and 11.9% had severe illness.
Statistical Information
P-Value
0.012
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website